Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Alabama
Clinical trial register · United States · industry-sponsored

Clinical Trials in Alabama, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9159 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Oct 2026, 03:16 UTC
9159
Studies in scope
industry-sponsored, all four open statuses
4974
Recruiting now
open to new participants
2202
Lead sponsors
across recruiting studies
Top states
California 5324 Florida 4464 Illinois 2496 Georgia 2367 Arizona 2252
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca67 Novartis Pharmaceuticals50 Eli Lilly and Company49 AbbVie44 Hoffmann-La Roche38
State
California5324 Florida4464 Illinois2496 Georgia2367 Arizona2252
All 51 states
Target enrolment
to

Trials with a site in Alabama

1301 of 9159 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
By invitation
AbbVie
Phase 3
1,200
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-01-14
Recruiting
AbbVie
Phase 3
1,059
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-01-13
Active, closed
Guardant Health, Inc.
Observational
12,000
Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2022-01-13
Active, closed
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT05099770Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Prokidney
Phase 3
685
Alabama, Arizona, California, Delaware, Florida, Georgia, Idaho, Illinois
2022-01-05
Active, closed
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
DrugTirabrutinib
Ono Pharmaceutical Co., Ltd.
Phase 2
119
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2021-12-29
Active, closed
ModernaTX, Inc.
Phase 1/2
867
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa
2021-12-28
Active, closed
INSPIRE Pipeline™ Shield Post Approval Study
NCT05071963Intracranial Aneurysm
Medtronic Neurovascular Clinical Affairs
Observational
246
Alabama, Connecticut, Florida, Georgia, Illinois, Kentucky, Missouri, New York
2021-12-20
Active, closed
Chiesi Farmaceutici S.p.A.
Phase 3
69
Alabama, California, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri
2021-12-17
Active, closed
Sanofi
Phase 4
1,339
Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Louisiana
2021-12-16
Recruiting
ViTAA Medical Solutions
Observational
200
Alabama, Massachusetts, North Carolina, Washington
2021-12-15
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Alabama, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts, New Mexico
2021-12-10
Active, closed
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
NCT05079282Relapsed or Refractory T Cell Lymphoma
DrugONO-4685
Ono Pharmaceutical Co., Ltd.
Phase 1
217
Alabama, California, Connecticut, Georgia, Massachusetts, Michigan, Missouri, New Jersey
2021-12-10
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 2
222
Alabama, Arkansas, Delaware, Florida, Georgia, Iowa, Massachusetts, Michigan
2021-12-01
Recruiting
Blueprint Medicines Corporation
Phase 2/3
534
Alabama, California, Colorado, Georgia, Massachusetts, Michigan, Minnesota, New York
2021-11-30
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia
2021-11-23
Active, closed
GlaxoSmithKline
Phase 2
305
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Indiana, Kentucky
2021-11-18
Recruiting
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT05143996Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
DrugCLN-049
Cullinan Therapeutics Inc.
Phase 1
60
Alabama, California, Florida, Georgia, Massachusetts, New York, North Carolina, Ohio
2021-11-18
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Alabama, Arizona, California, Colorado, Florida, Georgia, Mississippi, Nebraska
2021-11-17
Active, closed
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
NCT05020015Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Takeda
Phase 2
27
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Michigan, New York
2021-11-12
Active, closed
Sanofi
Phase 2
109
Alabama, Arizona, California, Florida, New Mexico, New York, Oklahoma, Tennessee
2021-11-10
Recruiting
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
NCT04996875Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
DrugBezuclastinib
Cogent Biosciences, Inc.
Phase 2
140
Alabama, Arizona, California, Florida, Georgia, Illinois, Massachusetts, New York
2021-11-09
Recruiting
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216Acute Stroke, Ischemic Stroke, Stroke
DiaMedica Therapeutics Inc
Phase 2/3
728
Alabama, California, Florida, Georgia, Illinois, Kansas, Louisiana, Massachusetts
2021-11-07
Active, closed
AlloSure Lung Assessment and Metagenomics Outcomes Study
NCT05050955Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
CareDx
Observational
550
Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Maryland
2021-10-29
Active, closed
Cullinan Therapeutics Inc.
Phase 1
440
Alabama, California, Florida, Massachusetts, Michigan, New Jersey, New York, North Carolina
2021-10-29
Active, closed
Hoffmann-La Roche
Phase 3
303
Alabama, Arkansas, California, Florida, Michigan, New York, North Carolina, Ohio
2021-10-26
Active, closed
Harmony TPV Post-Approval Study
NCT05077774Congenital Heart Disease, Tetrology of Fallot, RVOT Anomaly, Pulmonary Regurgitation
Medtronic Cardiovascular
Not applicable
174
Alabama, California, Colorado, Florida, Illinois, Massachusetts, Michigan, Missouri
2021-10-25
Recruiting
Hoffmann-La Roche
Phase 1
542
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2021-10-22
By invitation
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
NCT04987229Bipolar I Disorder, Schizophrenia
DrugOLZ/SAM
Alkermes, Inc.
Phase 3
236
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2021-10-22
Active, closed
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
NCT05198674Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
1,899
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2021-10-20
By invitation
ByHeart
Observational
2,000
Alabama, Arizona, Arkansas, Idaho, Ohio, South Carolina, Tennessee, Utah
2021-10-19
Recruiting
ConsideRAte Study - Splenic Stimulation for RA
NCT05003310Rheumatoid Arthritis
DrugBaricitinib
Galvani Bioelectronics
Not applicable
28
Alabama, California, Maryland, New York, Oregon, Pennsylvania, Texas
2021-10-19
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Alabama, California, Connecticut, Georgia, Massachusetts, Michigan, Ohio, Pennsylvania
2021-10-14
Recruiting
TransMedics
Observational
100,000
Alabama, Arizona, California, Florida, Georgia, Kentucky, Massachusetts, Michigan
2021-10-14
Active, closed
TransMedics
Observational
166
Alabama, California, Georgia, Massachusetts, Michigan, Nebraska, North Carolina, Texas
2021-10-14
Recruiting
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872Aortic Stenosis, Calcific, Aortic Valve Stenosis
Edwards Lifesciences
Not applicable
2,250
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2021-10-12
Active, closed
Beeline Medicines Corporation
Phase 2
248
Alabama, California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland
2021-10-11
Active, closed
Janssen Research & Development, LLC
Phase 1
166
Alabama, California, Colorado, Georgia, Indiana, New Jersey, New York, North Carolina
2021-09-22
Recruiting
Endologix
Not applicable
450
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Iowa, Kentucky
2021-09-20
Recruiting
BeOne Medicines
Phase 1/2
246
Alabama, California, Florida, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2021-09-16
Active, closed
Celgene
Phase 1
224
Alabama, Arizona, California, Florida, Georgia, Kansas, Minnesota, Nebraska
2021-09-15
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
689
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2021-09-13
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
Guardant Health, Inc.
Observational
2,285
Alabama, Arizona, Arkansas, California, Colorado, Florida, Louisiana, Maine
2021-09-07
Active, closed
Pfizer
Phase 3
38,861
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2021-08-31
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Alabama, California, Colorado, Connecticut, Florida, Illinois, Kansas, Kentucky
2021-08-27
Active, closed
Eli Lilly and Company
Phase 3
2,996
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2021-08-27
Active, closed
Inventiva Pharma
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2021-08-19
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Alabama, Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia
2021-08-14
Active, closed
Regeneron Pharmaceuticals
Observational
717
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2021-08-12
Active, closed
Boston Scientific Corporation
Phase 4
544
Alabama, California, Delaware, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2021-08-02
Recruiting
Novartis Pharmaceuticals
Phase 1/2
222
Alabama, California, Florida, Illinois, Iowa, Michigan, Minnesota, Missouri
2021-07-30
By invitation
UCB Biopharma SRL
Phase 3
760
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2021-07-27
Active, closed
AbbVie
Phase 3
132
Alabama, California, Florida, Illinois, Nevada, Ohio, South Carolina, West Virginia
2021-07-24
Recruiting
Bristol-Myers Squibb
Phase 3
102
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts
2021-07-21
Active, closed
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed
Eli Lilly and Company
Phase 1/2
540
Alabama, California, Connecticut, Florida, Indiana, Louisiana, Massachusetts, New Hampshire
2021-07-19
Active, closed
Biogen
Phase 3
562
Alabama, Arizona, California, Florida, Georgia, Illinois, Massachusetts, Missouri
2021-07-16
Active, closed
Bristol-Myers Squibb
Phase 3
729
Alabama, California, Illinois, Kentucky, Louisiana, Maryland, Michigan, Minnesota
2021-07-15
Recruiting
Valved Graft PMCF Study
NCT04754217Aortic Valve Disease, Ascending Aorta Abnormality, Aortic Dissection
Abbott Medical Devices
Observational
260
Alabama, Michigan, North Carolina, Pennsylvania
2021-07-13
Active, closed
FT819 in Subjects With B-cell Malignancies
NCT04629729Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
DrugsFT819·Fludara·Aldesleukin·Bendamustine
Fate Therapeutics
Phase 1
54
Alabama, Arizona, California, Florida, Iowa, Kansas, Kentucky, Minnesota
2021-07-12
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
810
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii
2021-07-09
Active, closed
Boehringer Ingelheim
Phase 1
554
Alabama, California, District of Columbia, Florida, Georgia, Hawaii, New York, North Carolina
2021-07-02
Active, closed
Gilead Sciences
Phase 3
3,292
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2021-06-28
Active, closed
Neurocrine Biosciences
Phase 3
103
Alabama, California, Colorado, Connecticut, District of Columbia, Georgia, Indiana, Massachusetts
2021-06-25
Active, closed
Mirati Therapeutics Inc.
Phase 3
461
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2021-06-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2021-06-18
By invitation
Philips Clinical & Medical Affairs Global
Not applicable
3,212
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2021-06-17
Active, closed
Janssen Research & Development, LLC
Phase 3
1,054
Alabama, Arizona, California, Florida, Maryland, Michigan, Missouri, Montana
2021-06-17
Recruiting
Device Global Registry for the IlluminOss Bone Stabilization System
NCT05206981Traumatic Fracture, Pathological Fracture
IlluminOss Medical, Inc.
Observational
300
Alabama, California, Colorado, Florida, Indiana, New York, North Carolina, Pennsylvania
2021-06-11
Active, closed
Assessing Outcomes With Microprocessor Knee Utilization in a K2 Population
NCT04784429Lower Limb Amputation Above Knee (Injury), Congenital Amputation of Lower Limb, Lower Limb Amputation Knee
Otto Bock Healthcare Products GmbH
Not applicable
107
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2021-06-11
Recruiting
Novartis Pharmaceuticals
Phase 4
130
Alabama, District of Columbia, Georgia, North Carolina, Pennsylvania, Texas
2021-06-10
Active, closed
AstraZeneca
Phase 3
367
Alabama, Arizona, California, Colorado, Florida, Idaho, Michigan, New Jersey
2021-06-08
Active, closed
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma
DrugsFludarabine·Cyclophosphamide
Caribou Biosciences, Inc.
Phase 1
72
Alabama, Arizona, Arkansas, California, Florida, Georgia, Iowa, Kentucky
2021-05-26
Active, closed
Nobel Biocare
Observational
1,000
Alabama, Illinois, New York, Oregon
2021-05-26
Active, closed
Biogen
Phase 3
548
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Louisiana, Michigan
2021-05-25
Recruiting
DALY II USA/ MB-CART2019.1 for DLBCL
NCT04792489Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL)
DrugsZamtocabtagene autoleucel·Bendamustine·Fludarabine·Cyclophosphamide
Miltenyi Biomedicine GmbH
Phase 2
315
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2021-05-25
Active, closed
Pfizer
Phase 3
599
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2021-05-12
Active, closed
Incyte Corporation
Phase 3
899
Alabama, California, Colorado, Florida, Hawaii, Kansas, Kentucky, Maryland
2021-05-11
Active, closed
Boston Scientific Corporation
Phase 3
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2021-05-11
Recruiting
Sellas Life Sciences Group
Phase 1/2
160
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Massachusetts
2021-05-10
By invitation
Cytokinetics
Phase 2/3
900
Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia
2021-05-06
Active, closed
Hoffmann-La Roche
Phase 2
586
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas
2021-05-05
Active, closed
Hoffmann-La Roche
Phase 3
1,188
Alabama, California, Florida, Georgia, Iowa, Maine, New Jersey, North Carolina
2021-05-04
Recruiting
Ventral or Inguinal Hernia, Robotically Repaired With OviTex Mesh
NCT04779918Hernia, Ventral, Hernia, Inguinal
Tela Bio Inc
Not applicable
160
Alabama, Colorado, Florida, Kansas, Kentucky, Michigan, New York, Texas
2021-04-29
Recruiting
Alnylam Pharmaceuticals
Observational
150
Alabama, Arizona, California, Maryland, Massachusetts, Minnesota, New York, North Carolina
2021-04-26
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
DrugPhase 2
enGene, Inc.
Phase 1/2
350
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2021-04-22
Active, closed
Breast Cancer Index (BCI) Registry
NCT04875351Breast Cancer
Biotheranostics, Inc.
Observational
3,465
Alabama, Arizona, California, Colorado, Florida, Illinois, Maryland, New York
2021-04-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2021-04-14
Active, closed
COMPASSION S3 Post-Approval Study
NCT04860765Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Edwards Lifesciences
Observational
150
Alabama, California, Colorado, Illinois, Massachusetts, Minnesota, Missouri, New Jersey
2021-04-13
Active, closed
Abiomed Inc.
Not applicable
1,252
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2021-04-13
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky
2021-04-09
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2021-04-01
Active, closed
Hoffmann-La Roche
Phase 3
751
Alabama, Arizona, California, District of Columbia, Florida, Indiana, Kansas, Massachusetts
2021-03-24
Active, closed
Hoffmann-La Roche
Phase 3
746
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Louisiana
2021-03-17
Active, closed
Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD
NCT04591392Heart Septal Defect, Heart Septal Defects, Atrial, Heart Defects, Congenital, Cardiovascular Abnormalities
atHeart Medical
Not applicable
250
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2021-03-12
Active, closed
Janssen Research & Development, LLC
Phase 1
140
Alabama, California, Colorado, Georgia, Indiana, Missouri, New Jersey, New York
2021-03-12
Active, closed
Karyopharm Therapeutics Inc
Phase 3
353
Alabama, California, Colorado, Connecticut, District of Columbia, Kentucky, Maryland, Michigan
2021-03-11
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2021-03-09
Recruiting
Syndax Pharmaceuticals
Phase 2
296
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana
2021-03-04
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
DrugRuxolitinib
Incyte Corporation
Phase 1
140
Alabama, Colorado, Florida, Georgia, Iowa, Missouri, New Jersey, New York
2021-02-23
Active, closed
Hoffmann-La Roche
Phase 3
270
Alabama, California, Florida, Maryland, Massachusetts, Mississippi, New Jersey, New York
2021-02-23
Recruiting
Upsher-Smith Laboratories
Phase 4
132
Alabama, California, Colorado, Connecticut, Florida, Michigan, Mississippi, Missouri
2021-02-19
Active, closed
Shanghai MicroPort Medical (Group) Co., Ltd.
Not applicable
1,720
Alabama, Arizona, California, Connecticut, Florida, Georgia, Indiana, Kansas
2021-02-17
Active, closed
GlaxoSmithKline
Phase 3
1,720
Alabama, Arizona, California, Florida, Indiana, Kansas, Minnesota, Missouri
2021-02-15
Active, closed
Sellas Life Sciences Group
Phase 3
127
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, New York
2021-02-08
Recruiting
AB Science
Phase 3
495
Alabama, California, Kentucky, Maryland, Massachusetts, Virginia
2021-02-02
Active, closed
Anthos Therapeutics, Inc.
Phase 2
1,287
Alabama, Connecticut, Florida, Georgia, Kentucky, Maryland, Massachusetts, Michigan
2021-02-02
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Alabama, Arkansas, California, Florida, Georgia, Illinois, Kentucky, Michigan
2021-02-01
Active, closed
Forma Therapeutics, Inc.
Phase 3
450
Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia
2021-01-29
Active, closed
AstraZeneca
Phase 3
1,371
Alabama, Arkansas, California, Colorado, Florida, Indiana, Louisiana, Maryland
2021-01-28
Recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
DrugsIrinotecan·Gemcitabine
Artios Pharma Ltd
Phase 1/2
542
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2021-01-27
Recruiting
Pfizer
Phase 3
2,100
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2021-01-15
Active, closed
Galderma R&D
Phase 3
500
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Kansas
2021-01-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2021-01-10
Active, closed
MYLUNG Consortium Study Protocol 2
NCT05644808Carcinoma, Non-Small-Cell Lung
US Oncology Research
Observational
1,002
Alabama, Colorado, Florida, Illinois, Maryland, Minnesota, New York, Ohio
2020-12-29
Recruiting
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
NCT04592445Heart Failure With Preserved Ejection Fraction (HFpEF
Axon Therapies, Inc.
Not applicable
150
Alabama, Arizona, California, Georgia, Illinois, Indiana, Louisiana, Michigan
2020-12-18
Active, closed
Janssen Research & Development, LLC
Phase 1/2
228
Alabama, Arkansas, Colorado, Georgia, Minnesota, Missouri, New York, North Carolina
2020-12-15
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts
2020-12-11
Active, closed
Hoffmann-La Roche
Phase 3
769
Alabama, Arizona, California, Colorado, Florida, Kentucky, Maryland, Massachusetts
2020-12-03
Active, closed
PARADIGM: Amplatzer Valvular Plug for PVL Closure
NCT04489823Paravalvular Aortic Regurgitation
Abbott Medical Devices
Not applicable
200
Alabama, Georgia, Massachusetts, Minnesota, Missouri, Nebraska, New Jersey, New York
2020-12-01
Active, closed
Hoffmann-La Roche
Phase 3
864
Alabama, Arizona, California, Colorado, Florida, Indiana, Kansas, Louisiana
2020-11-26
Active, closed
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
DrugsEpcoritamab·Pirtobrutinib·Lenalidomide·Venetoclax
Genmab
Phase 1/2
194
Alabama, California, Florida, Maryland, Massachusetts, Michigan, New Jersey, New York
2020-11-25
Active, closed
Eli Lilly and Company
Phase 3
312
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2020-11-25
Active, closed
Medicago
Phase 2/3
30,918
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Illinois
2020-11-19
Active, closed
The ENCIRCLE Trial
NCT04153292Mitral Regurgitation, Mitral Valve Insufficiency
Edwards Lifesciences
Not applicable
786
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2020-11-12
Active, closed
Genmab
Phase 1/2
543
Alabama, California, Massachusetts, Michigan, New Jersey, New York, North Carolina, Texas
2020-11-03
Active, closed
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT04452591Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
DrugCretostimogene Grenadenorepvec
CG Oncology, Inc.
Phase 3
190
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2020-10-27
Active, closed
Hoffmann-La Roche
Phase 3
985
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Indiana, Kansas
2020-10-26
Recruiting
Abbott Vascular Medical Device Registry
NCT04573660Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism
Abbott Medical Devices
Observational
3,784
Alabama, Arkansas, California, Illinois, Nebraska, Ohio, Tennessee
2020-10-25
By invitation
Genetix Biotherapeutics Inc.
Observational
85
Alabama, California, Georgia, Illinois, Maryland, Minnesota, New Jersey, New York
2020-10-21
Active, closed
Bayer
Phase 3
402
Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Maryland
2020-10-20
Recruiting
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
NCT04471909Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
Endospan Ltd.
Not applicable
110
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2020-10-20
Active, closed
TTVR Early Feasibility Study
NCT04433065Tricuspid Regurgitation
Medtronic Cardiovascular
Not applicable
150
Alabama, Arizona, California, Connecticut, Georgia, Michigan, Minnesota, Montana
2020-10-20
Active, closed
CHAMPION-AF Clinical Trial
NCT04394546Atrial Fibrillation, Stroke, Bleeding
DrugsNon-Vitamin K Anticoagulant·NOAC
Boston Scientific Corporation
Not applicable
3,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2020-10-15
Active, closed
Nyxoah S.A.
Not applicable
115
Alabama, Florida, Georgia, Indiana, Iowa, Massachusetts, New York, Ohio
2020-10-14
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Alabama, Arizona, California, Colorado, Connecticut, Florida, Indiana, Louisiana
2020-09-23
Active, closed
argenx
Phase 2
229
Alabama, Arizona, California, Colorado, Florida, Iowa, Kansas, Kentucky
2020-09-18
Active, closed
Janssen Research & Development, LLC
Phase 2
194
Alabama, California, Georgia, Michigan, New York, North Carolina, Pennsylvania
2020-09-17
Recruiting
Epygenix
Phase 3
150
Alabama, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Illinois
2020-09-15
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
240
Alabama, California, Florida, Kansas, Maryland, Michigan, Missouri, Ohio
2020-08-20
Active, closed
Hoffmann-La Roche
Phase 3
271
Alabama, California, Colorado, Connecticut, Florida, Georgia, New York, Ohio
2020-08-10
Active, closed
AbbVie
Phase 3
800
Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida
2020-08-10
Active, closed
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847Myelodysplastic Syndrome, Acute Myeloid Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
170
Alabama, California, Colorado, Kansas, Kentucky, Massachusetts, Michigan, Missouri
2020-08-07
Active, closed
Incyte Corporation
Phase 2
112
Alabama, Arizona, California, Colorado, Illinois, Kansas, Maryland, Massachusetts
2020-08-03
Active, closed
MitraClip REPAIR MR Study
NCT04198870Mitral Valve Regurgitation
Abbott Medical Devices
Not applicable
500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2020-07-21
Active, closed
Eisai Inc.
Phase 3
1,400
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2020-07-14
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
160
Alabama, Florida, Georgia
2020-07-13
Active, closed
RETHINK REFLUX Registry
NCT04253392Gastroesophageal Reflux
Ethicon Endo-Surgery
Observational
500
Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Michigan
2020-07-08
Active, closed
Amplatzer Amulet LAAO vs. NOAC
NCT04226547Atrial Fibrillation, Stroke, Bleeding
DrugNOAC
Abbott Medical Devices
Not applicable
2,650
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2020-07-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Alabama, Arkansas, California, Florida, Indiana, Kentucky, Massachusetts, Michigan
2020-07-06
Active, closed
Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication
NCT042525731 Paravisceral Abdominal Aortic Aneurysm, 2 Juxtarenal Abdominal Aortic Aneurysm, 3 Pararenal Abdominal Aortic Aneurysm, 4 Complex Abdominal Aortic Aneurysms
Endologix
Not applicable
13
Alabama, District of Columbia, Georgia, Indiana, Missouri, New Jersey, New York, Oregon
2020-06-29
Active, closed
Eli Lilly and Company
Phase 3
996
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Indiana
2020-06-22
Active, closed
Protection Against Emboli During Carotid Artery Stenting Using the Neuroguard IEP System
NCT04201132Carotid Artery Stenosis, Carotid Artery Diseases, Carotid Stenosis
Contego Medical, Inc.
Not applicable
305
Alabama, California, District of Columbia, Florida, Iowa, Kentucky, Louisiana, Maryland
2020-06-12
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Alabama, Arizona, California, Colorado, Connecticut, Florida, Iowa, Kansas
2020-06-12
Active, closed
Epizyme, Inc.
Phase 3
599
Alabama, Arizona, California, Colorado, Florida, Illinois, Michigan, Minnesota
2020-06-11
Active, closed
Myriad Genetic Laboratories, Inc.
Observational
500
Alabama, California, Florida, Illinois, Maryland, Tennessee
2020-04-30
Active, closed
AstraZeneca
Phase 2
240
Alabama, California, Florida, Nebraska, Ohio, Tennessee, Wisconsin
2020-04-22
Active, closed
Micro Medical Solution, Inc.
Not applicable
177
Alabama, Arizona, California, Colorado, Florida, Iowa, Louisiana, Maryland
2020-03-31
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Alabama, California, Colorado, District of Columbia, Georgia, Illinois, Louisiana, Maryland
2020-02-27
Active, closed
Genetix Biotherapeutics Inc.
Phase 3
35
Alabama, District of Columbia, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas
2020-02-14
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Alabama, California, Georgia, Illinois, Massachusetts, Michigan, New York, Ohio
2020-02-11
Recruiting
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
NCT05986292Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
Eli Lilly and Company
Phase 2
10,000
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2020-01-30
Active, closed
Bayer
Observational
805
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas
2020-01-30
Recruiting
Eli Lilly and Company
Phase 2
105
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2020-01-22
Active, closed
MitraClip EXPAND G4 Study
NCT04177394Mitral Valve Regurgitation, Mitral Regurgitation
Abbott Medical Devices
Observational
1,164
Alabama, Arkansas, California, Connecticut, Florida, Illinois, Kansas, Minnesota
2020-01-17
Active, closed
PROACTIVE-HF IDE Trial Heart Failure NYHA Class III
NCT04089059Heart Failure NYHA Class III
Endotronix, Inc.
Not applicable
738
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2020-01-10
Recruiting
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
NCT04260022Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia
DrugBlinatumomab
Ascentage Pharma Group Inc.
Phase 1
242
Alabama, California, Georgia, Maryland, Ohio, Texas, Washington
2020-01-09
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
240
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2019-12-16
Active, closed
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
NCT03947619ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Abiomed Inc.
Not applicable
527
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2019-12-12
Active, closed
Cold Agglutinin Disease Real World Evidence Registry
NCT05791708Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
RECORDATI GROUP
Observational
429
Alabama, California, District of Columbia, Georgia, Illinois, Iowa, Massachusetts, Michigan
2019-12-12
Recruiting
Alexion Pharmaceuticals, Inc.
Observational
500
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2019-12-02
Active, closed
Zephyr Valve Registry (ZEVR)
NCT04186546Emphysema
Pulmonx Corporation
Observational
150
Alabama, Illinois, Michigan, Pennsylvania, Texas, Virginia, Wisconsin
2019-11-25
Active, closed
Natera, Inc.
Observational
5,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois
2019-11-06
Active, closed
Bristol-Myers Squibb
Phase 3
790
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Georgia, Illinois
2019-10-28
Active, closed
Bayer
Observational
371
Alabama, Arizona, California, Colorado, District of Columbia, Louisiana, Minnesota, North Carolina
2019-10-21
Active, closed
AstraZeneca
Phase 4
75
Alabama, California, Florida, Georgia, Indiana, Iowa, Kansas, Michigan
2019-10-08
Active, closed
Guardant Health, Inc.
Observational
44,467
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2019-10-08
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Alabama, Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky
2019-10-03
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2019-10-02
Active, closed
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
NCT04056247Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer
OncoHost Ltd.
Observational
10,000
Alabama, Florida, Illinois, Iowa, New Jersey, New York, Tennessee, Texas
2019-10-01
Active, closed
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 2
114
Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida
2019-09-29
Recruiting
LivaNova
Not applicable
6,800
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Kansas
2019-09-26
Active, closed
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
NCT03992404Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
DrugXeomin
Merz Pharmaceuticals GmbH
Phase 3
603
Alabama, Arkansas, California, Connecticut, Florida, Massachusetts, Missouri, New York
2019-09-16
Active, closed
UniQure Biopharma B.V.
Phase 1/2
43
Alabama, Arizona, California, Colorado, Illinois, Maryland, Michigan, Ohio
2019-09-06
Active, closed
Pfizer
Phase 3
896
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2019-09-05
Active, closed
TRILUMINATE Pivotal Trial
NCT03904147Tricuspid Regurgitation
Abbott Medical Devices
Not applicable
572
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2019-08-21
Active, closed
Sanofi
Observational
1,860
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2019-08-15
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois
2019-08-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Alabama, Arkansas, California, Colorado, District of Columbia, Georgia, Illinois, Indiana
2019-07-24
Active, closed
TARGET BP I Clinical Trial
NCT02910414Hypertension
DrugEthanol
Ablative Solutions, Inc.
Phase 3
300
Alabama, Georgia, North Carolina, Texas
2019-07-22
Active, closed
Novo Nordisk A/S
Phase 2
62
Alabama, California, Idaho, Minnesota, New Jersey, New York, Ohio, Oklahoma
2019-07-04
Active, closed
Novartis Pharmaceuticals
Phase 2
121
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2019-06-24
Active, closed
W.L.Gore & Associates
Not applicable
102
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2019-06-17
Active, closed
Boston Scientific Corporation
Not applicable
1,948
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2019-06-10
Active, closed
Nuvaira, Inc.
Not applicable
464
Alabama, Arizona, California, Florida, Illinois, Kentucky, Massachusetts, Michigan
2019-05-23
Active, closed
Blueprint Medicines Corporation
Phase 2
251
Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Massachusetts
2019-04-16
Active, closed
Sun Pharmaceutical Industries, Inc.
Phase 2/3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Idaho
2019-04-04
Recruiting
AstraZeneca
Phase 3
140
Alabama, Georgia, Maryland, Michigan, Missouri, New Jersey, New York, North Carolina
2019-04-02
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
1,759
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2019-03-28
Active, closed
AbbVie
Phase 3
964
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2019-03-25
Recruiting
Aptose Biosciences Inc.
Phase 1/2
240
Alabama, California, Connecticut, Florida, Georgia, Massachusetts, North Carolina, Ohio
2019-03-11
Active, closed
AstraZeneca
Phase 3
724
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Georgia, Illinois
2019-03-06
Active, closed
Xenon Pharmaceuticals Inc.
Phase 2
325
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii
2019-01-30
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois
2019-01-25
Active, closed
Kartos Therapeutics, Inc.
Phase 2
20
Alabama, California, Missouri, Ohio
2019-01-15
Active, closed
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
DrugsAdagrasib·Afatinib·Cetuximab·Pembrolizumab
Mirati Therapeutics Inc.
Phase 1/2
731
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2019-01-15
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Hawaii
2018-12-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2018-12-27
Active, closed
Idorsia Pharmaceuticals Ltd.
Phase 3
107
Alabama, California, Florida, Illinois, Iowa, Massachusetts, Michigan, Pennsylvania
2018-12-18
Active, closed
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
NCT03614260Hypertension, Vascular Diseases, Cardiovascular Diseases
ReCor Medical, Inc.
Not applicable
224
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Louisiana
2018-12-14
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2018-12-07
Active, closed
AstraZeneca
Phase 3
1,063
Alabama, California, Connecticut, Illinois, Iowa, Kansas, Kentucky, Louisiana
2018-11-16
Active, closed
AstraZeneca
Phase 3
895
Alabama, Alaska, Arizona, California, Colorado, Illinois, Indiana, Louisiana
2018-10-31
Active, closed
Kolon TissueGene, Inc.
Phase 3
535
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Louisiana
2018-10-30
Active, closed
AbbVie
Phase 2
270
Alabama, Arizona, Arkansas, California, Colorado, Florida, Hawaii, Illinois
2018-10-10
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Vincristine
Takeda
Phase 3
245
Alabama, California, Georgia, Indiana, Kansas, Maryland, New Jersey, New York
2018-10-04
Active, closed
AstraZeneca
Phase 3
1,246
Alabama, California, Connecticut, District of Columbia, Florida, Illinois, Indiana, Kansas
2018-09-27
Active, closed
Hoffmann-La Roche
Phase 1/2
422
Alabama, California, Colorado, Florida, Michigan, New York, North Carolina, Pennsylvania
2018-09-25
Active, closed
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
NCT03393884Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsIMNN-001·Paclitaxel·Carboplatin
Imunon
Phase 1/2
130
Alabama, California, Florida, Massachusetts, Missouri, New Jersey, New York, Oklahoma
2018-09-05
Active, closed
AbbVie
Phase 3
1,533
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2018-08-09
Active, closed
C. R. Bard
Not applicable
213
Alabama, California, Connecticut, Iowa, Kentucky, Louisiana, Maryland, Massachusetts
2018-08-07
Recruiting
Celgene
Phase 2/3
1,541
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2018-07-19
Active, closed
Eli Lilly and Company
Phase 3
1,058
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2018-07-18
Active, closed
X-linked Hypophosphatemia Disease Monitoring Program
NCT03651505X-linked Hypophosphatemia, Hypophosphatemic Rickets
Ultragenyx Pharmaceutical Inc
Observational
782
Alabama, California, Colorado, Connecticut, Illinois, Indiana, Maryland, Massachusetts
2018-07-16
Active, closed
Abbott Medical Devices
Not applicable
103
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2018-06-15
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
890
Alabama, Massachusetts, Minnesota, New York, Ohio, Oklahoma, Tennessee, Texas
2018-05-21
Active, closed
CeraPedics, Inc
Not applicable
290
Alabama, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2018-04-24
Active, closed
Bristol-Myers Squibb
Phase 3
545
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Louisiana
2018-04-18
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2018-04-13
Active, closed
Merck Sharp & Dohme LLC
Phase 2
340
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2018-04-09
Active, closed
Regeneron Pharmaceuticals
Observational
858
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2018-04-06
Active, closed
AbbVie
Phase 3
747
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2018-03-21
Active, closed
AstraZeneca
Phase 2
154
Alabama, Arizona, Florida, Kentucky, New York, Pennsylvania, Tennessee, Washington
2018-03-16
Active, closed
Eli Lilly and Company
Phase 3
533
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2018-03-14
Active, closed
AstraZeneca
Phase 2
273
Alabama, Alaska, Arizona, Colorado, Connecticut, Illinois, Indiana, Kentucky
2018-03-07
Active, closed
AMPLATZER PFO Occluder Post Approval Study
NCT03309332Stroke, Patent Foramen Ovale
Abbott Medical Devices
Not applicable
1,214
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2018-01-31
Active, closed
EBR Systems, Inc.
Not applicable
300
Alabama, California, Florida, Georgia, Illinois, Indiana, Iowa, Kansas
2018-01-17
Active, closed
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
NCT03386513Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
DrugIMGN632
AbbVie
Phase 1/2
179
Alabama, Arizona, California, Florida, Maryland, Massachusetts, New York, North Carolina
2018-01-02
Recruiting
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
Massive Bio, Inc.
Observational
50,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida
2018-01-01
Active, closed
W.L.Gore & Associates
Not applicable
175
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Louisiana
2017-12-19
Active, closed
Janssen Research & Development, LLC
Phase 1
279
Alabama, California, Colorado, New York, Tennessee
2017-12-16
Active, closed
Juno Therapeutics, a Subsidiary of Celgene
Phase 1/2
320
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2017-11-27
Active, closed
ViiV Healthcare
Phase 3
1,049
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2017-10-27
Recruiting
Medtronic Cardiovascular
Not applicable
1,056
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2017-10-23
Active, closed
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
DrugsVusolimogene Oderparepvec·Opdivo·Nivolumab
Replimune, Inc.
Phase 2
340
Alabama, Arizona, Arkansas, California, Florida, Iowa, Kentucky, Minnesota
2017-09-20
Active, closed
Eli Lilly and Company
Phase 3
5,637
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2017-07-12
Active, closed
The REPLACE Registry for Cholbam® (Cholic Acid)
NCT03115086Bile Acid Synthesis Disorders
Mirum Pharmaceuticals, Inc.
Observational
55
Alabama, California, Florida, Georgia, Indiana, Louisiana, Minnesota, Missouri
2017-07-10
Active, closed
Hoffmann-La Roche
Phase 2
316
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas
2017-06-27
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois
2017-06-26
Active, closed
Bolton Medical
Not applicable
110
Alabama, Arizona, California, Connecticut, Florida, Georgia, Indiana, Iowa
2017-05-10
Recruiting
Agendia
Observational
30,000
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2017-04-28
Active, closed
AstraZeneca
Phase 3
987
Alabama, Arizona, Arkansas, California, Connecticut, Georgia, Indiana, Kansas
2017-03-27
Active, closed
Abbott Medical Devices
Not applicable
2,005
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2017-03-27
Recruiting
Stryker Instruments
Observational
8,000
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2017-03-10
Active, closed
LEADERS FREE II: BioFreedom™ Pivotal Study
NCT02843633Acute Coronary Syndrome, High Bleeding Risk
Biosensors Europe SA
Not applicable
1,203
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Idaho, Illinois
2017-02-14
Active, closed
AbbVie
Phase 3
950
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2017-01-31
Active, closed
AbbVie
Phase 2
120
Alabama, Arkansas, Florida, Georgia, Illinois, Indiana, Kentucky, Maine
2017-01-19
Active, closed
Ribociclib (LEE011) Rollover Study for Continued Access
NCT02934568Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
DrugRibociclib
Novartis Pharmaceuticals
Phase 2
22
Alabama, Massachusetts, Michigan, New York, Tennessee
2016-12-15
Active, closed
ViiV Healthcare
Phase 3
618
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2016-10-28
Active, closed
ViiV Healthcare
Phase 3
631
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Indiana, Minnesota
2016-10-27
Recruiting
MEASuRE: Metreleptin Effectiveness And Safety Registry
NCT02325674Generalised Lipodystrophy, Partial Lipodystrophy
DrugMetreleptin
Chiesi Farmaceutici S.p.A.
Observational
100
Alabama, California, Georgia, Illinois, Kansas, Louisiana, Maryland, Michigan
2016-10-11
Active, closed
Memory Gel and Shape Combined Cohort
NCT02919592Primary Breast Augmentation, Primary Breast Reconstruction, Revision Breast Augmentation, Revision Breast Reconstruction
Mentor Worldwide, LLC
Not applicable
3,603
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2016-09-01
Recruiting
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
NCT02744677Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Edwards Lifesciences
Not applicable
108
Alabama, Arkansas, California, Colorado, Georgia, Kentucky, Massachusetts, Minnesota
2016-07-05
Recruiting
Collection and Distribution of Biospecimens for Novel Research Uses
NCT03848962Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases
iSpecimen Inc
Observational
10,000
Alabama, Massachusetts
2016-06-30
Active, closed
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
NCT02716116Carcinoma, Non-Small-Cell Lung
DrugMobocertinib
Takeda
Phase 1/2
334
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2016-06-16
Recruiting
Boston Scientific Corporation
Observational
100
Alabama, Idaho, Massachusetts, New Hampshire, New Jersey
2016-05
Active, closed
Biodesix, Inc.
Observational
5,006
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana
2016-04-04
Active, closed
Mentor Worldwide, LLC
Not applicable
400
Alabama, Arizona, California, Georgia, Indiana, Iowa, Kansas, Minnesota
2016-04-01
Active, closed
Tesaro, Inc.
Phase 1
729
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2016-03-07
Active, closed
ReCor Medical, Inc.
Not applicable
282
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana
2016-03
Active, closed
Edwards Lifesciences
Not applicable
1,000
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2016-03
Active, closed
MedImmune LLC
Phase 1/2
383
Alabama, Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts
2016-02-22
Active, closed
Geron Corporation
Phase 2/3
289
Alabama, Arizona, California, Connecticut, Florida, Indiana, Maryland, Missouri
2016-01-12
Active, closed
AbbVie
Phase 3
1,629
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2015-12-01
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2015-11-27
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2015-11-19
Active, closed
Regeneron Pharmaceuticals
Phase 3
880
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2015-10-15
Active, closed
Taiho Oncology, Inc.
Phase 1/2
253
Alabama, Arizona, California, Connecticut, Georgia, Illinois, Maryland, Massachusetts
2015-07-14
Active, closed
Medtronic
Observational
3,100
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Iowa
2015-07
Active, closed
A Trial of Vigil for Participants With Ovarian Cancer
NCT02346747Ovarian Cancer, Ovarian Neoplasms
Gradalis, Inc.
Phase 2
92
Alabama, California, Florida, Georgia, Kentucky, Maine, Massachusetts, Michigan
2015-02
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2014-12-17
Active, closed
AbbVie
Observational
1,446
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Louisiana
2014-08-28
Active, closed
ImmunityBio, Inc.
Phase 1/2
369
Alabama, Alaska, Arizona, Arkansas, California, Connecticut, Florida, Georgia
2014-07-21
Active, closed
Abbott Medical Devices
Not applicable
1,242
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2014-05
Active, closed
AstraZeneca
Phase 3
1,837
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2014-04-22
Recruiting
Photocure
Observational
4,400
Alabama, Arizona, California, District of Columbia, Georgia, Illinois, Indiana, Kansas
2014-04
Active, closed
Bolton Medical
Not applicable
158
Alabama, Arizona, Connecticut, Florida, Georgia, Illinois, Iowa, Massachusetts
2013-11-23
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Idaho
2013-10-14
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Alabama, California, Colorado, Connecticut, Florida, Illinois, Maryland, Massachusetts
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2013-08-26
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Alabama, California, Florida, Massachusetts, Michigan, New Jersey, Pennsylvania, Utah
2013-07-26
Active, closed
AbbVie
Observational
8,250
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2013-04-29
Active, closed
Bristol-Myers Squibb
Observational
2,555
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Iowa
2012-06-13
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2012-01
Active, closed
Medtronic Cardiac Rhythm and Heart Failure
Not applicable
64
Alabama, California, Florida, Illinois, Massachusetts, Minnesota, Texas, Wisconsin
2011-06
Recruiting
Sequenom, Inc.
Observational
2,000
Alabama, California, Illinois, Iowa, Michigan, New Jersey, South Carolina
2011-05
Recruiting
Caris Biorepository Research Protocol
NCT01499394Cancer, Early Detection of Cancer, Minimal Residual Disease
Caris Science, Inc.
Observational
100,000
Alabama, Arizona, Arkansas, Florida, Georgia, Illinois, Louisiana, Maryland
2010-11
Active, closed
Janssen Scientific Affairs, LLC
Observational
20,167
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2007-06-21
Active, closed
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
NCT00606346Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
Janssen Biotech, Inc.
Observational
4,970
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2007-05-31
Active, closed
PhII ICb With/Without Erbitux in MBC Pts
NCT00248287Metastatic Breast Cancer
DrugsErbitux·Irinotecan·Carboplatin
US Oncology Research
Phase 2
154
Alabama, Arizona, Colorado, Connecticut, Florida, Illinois, Indiana, Kansas
2005-07-28
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2004-09-15
Recruiting
Genzyme, a Sanofi Company
Observational
9,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2001-07-31
Recruiting
Medtronic
Observational
20,000
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia
1983-01
Rows per page Showing 1001–1301 of 1301
Previous 1 2 3
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 October 2026. https://priyalifescience.com/clinical-trials-usa/state/alabama?page=3

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,159 studies in total at the last sync on 22 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,301 of those studies with a site in Alabama.

How many clinical trials are recruiting in Alabama?

673 of the 1,301 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:16 UTC sync. A further 12 have not yet opened recruitment, 582 are active but closed to new participants, and 34 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.